Video gallery

Erik Penser – CEO Martin Jönsson gives a company presentation with regards to the ongoing rights issue December 6–20, 2022

Erik Penser – Interview with AlzeCure’s CEO Martin Jönsson regarding the ongoing rights issue December 6–20, 2022

Preclinical characterization of ACD856. Scientific presentation at the Ctad conference nov 29- 2dec, 2022

AC-0027875, a novel gamma-secretase modulator. Scientific presentation at the Ctad conference nov 29- 2dec, 2022

Quantitative EEG results from a multiple ascending dose study. Scientific presentation at the Ctad conference nov 29- 2dec, 2022

Martin Jönsson presented at Life Science Investor Conference, November 23, 2022

Carlsquare’s Investor Day on Life science, Nov. 17, 2022 (English)

Aktiespararna’s event with AlzeCure on November 16, 2022

CEO Martin Jönsson presented the company’s latest developments at Redeye Theme: Neurology on October 12, 2022

CEO Martin Jönsson presented an update on our Pain management projects at Redeye Theme: Neurology on October 12.

Martin talks about the latest developments for AlzeCure including the phase 2 study with ACD 440 against neuropathic pain, the new positive clinical results with NeuroRestore ACD 856, our new patent and the new results with the pain project TrkA-NAM. (Swedish) September 12, 2022

Watch the interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the latest clinical progress, September 1, 2022 (Swedish)

Watch the interview with Aktiespararna at Finwire with AlzeCure’s CEO Martin Jönsson. (Swedish) July 1, 2022

AlzeCure – Interview at Redeye with CEO Martin Jönsson about the phase II study with ACD440. (Swedish) June 23, 2022

AlzeCure at Redeye Growth Day June 2, 2022

CEO Martin Jönsson Presenting at Redeye Growth Day May 23, 2022

AlzeCure – Alzheimer event at Redeye 3 May, 2022 (Swedish)

Watch the Analysisguide’s interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the future. March 14, 2022 (Swedish)

CEO Martin Jönsson is interview by BioStock on the company’s latest developments, including the ongoing rights issue. March 14, 2022

CSO Johan Sandin explains the science behind AlzeCure’s project portfolio and what distinguishes it from other pharma companies. (Swedish) March 14, 2022

Watch the interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the ongoing issue. (Swedish)

See CEO Martin Jönsson and CSO Johan Sandin, present upcoming events in the company and the ongoing issue. (Swedish)

AlzeCure – New presentation at Penser. (Swedish)

CEO Martin Jönsson presents AlzeCure’s development, plans and success. 

Latest newsflow February 3. 2022 (Swedish)

CEO Martin Jönsson presents at Aktiespararna January 31, 2022 (Swedish)

AlzeCure Pharma – Kapitalmarknadsdag, Januari 18 2022

AlzeCure medverkar på Erik Penser Banks temadag Life Science, December 2, 2021

Follow us – Stay updated

AlzeCure Pharma – Redeye Life Science Day, November 11, 2021

AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans.

Alzecure presents at Healthcare Innovation Summit, October 7, 2021

Alzecure Pharma – Naventus Life Science Summit, September 29, 2021

Aktiespararna intervjuar VD Martin Jönsson – senaste kvartalsrapporten och framtidsutsikterna. 20 september, 2021

AlzeCure Pharma – Aktiedagen Stockholm, September 7 2021

Strategy Update on Alzheimer’s Disease & NeuroRestore, September 1, 2021

Alzheimer’s disease and the neurotrophins BDNF/NGF by by Prof. Maria Eriksdotter M.D., PhD, Prof, September 1, 2021

Company Overview & Vision by Martin Jönsson CEO, September 1, 2021

NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research, September 1, 2021

Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer, September 1, 2021

Om AlzeCures uppkomst och utveckling – Ett embryo som kan bli något stort –

med Bengt Winblad, professor, senior vid Karolinska Institutet

Om Alzstatin och läkemedel vid Alzheimers sjukdom –

med Bengt Winblad, professor, senior vid Karolinska Institutet”

Om att drabbas av Alzheimers sjukdom, diagnostik, vården idag samt framtida behov –

med Bengt Winblad, professor, senior vid Karolinska Institutet”

Negative Allosteric Modulators of TrkA for the Treatment of Pain – Scientific presentation at the IASP conference on pain, June 2021

Alzecure: CEO Martin Jönsson present at Redeye Growth Day

TrkA- NAM – Project in osteoarthritis & other severe pain conditions Head of Discovery & Research Pontus Forsell

ACD 440 – A novel VR1 antagonist for neuropathic pain CSO Johan Sandin

Chronic Pain – a high unmet medical need CMO Märta Segerdahl

Company overview and goals CEO Martin Jönsson

CEO Martin Jönsson after the company’s annual meeting

Interview with Martin Jönsson CEO in Aktiespararna’s analysis guide

CEO Martin Jönsson presentation, Aktiedagen Lund

Interview with Johan Sandin (CSO) in Aktiespararna’s analysis guide

AlzeCure Pharma provides a scientific update on Alzheimer’s disease and the Alzstatin project platform

Presentation with Redeye – Science & Market update – September 1, 2020

Welcome to AlzeCure…

CEO presentation video – Annual meeting May 20 2020 (Swedish)

Lär känna vd Martin Jönsson – Redeye Research Interview March 19, 2020 (Swedish)

Aktiedagen March 16, 2020 (Swedish)

About Alzstatin

About Alzheimers disease

About NeuroRestore